ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0542

Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?

Marta Flores1, Juan de Luque2, Mitndbaim Parra3, Alejandro Escudero Contreras4, María Dolores López-Montilla5 and Clementina López Medina6, 11. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, 2Reina Sofia University Hospital, CÓRDOBA, Andalucia, Spain, 31. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, 4IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 5Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, 6Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain

Meeting: ACR Convergence 2025

Keywords: Pathology Bone Joint, Psoriatic arthritis, risk factors, Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Psoriatic arthritis (PsA) is a debilitating disease that occurs in up to one-third of patients with psoriasis (Pso), generally manifesting after the onset of Pso. Numerous studies have analyzed the risk factors for the development of PsA in patients with Pso, highlighting family history. However, there is little evidence about what determines the latency period between the onset of Pso and the development of arthritis.Therefore, the following objectives have been established for this study:a) To analyze the clinical phenotype of PsA based on the presence or absense of a family history of Pso or PsA (FH Pso/PsA)b) To determine which factors (including FH Pso/PsA) influence the speed of onset of arthritis after the initial presentation of Pso

Methods: We conducted a retrospective analytical study including 359 patients diagnosed with PsA according to the “Classification Criteria for Psoriatic Arthritis” (CASPAR). These patients were divided based on the presence or absence of a family history of Pso/PsA (FH Pso/PsA). We collected clinical, radiographic, and treatment variables for each patient, as well as the dates of onset of Pso and arthritis. For the comparison of variables, Student’s t-test (for quantitative variables) and Chi-square test (for qualitative variables) were used. We designed a survival analysis with Cox multiple regression to determine which factors influence the speed of onset of arthritis after the initial presentation of Pso.

Results: Of the 359 patients included, 37.5% had a family history of Pso/PsA (FH Pso/PsA). Patients with FH showed cutaneous-onset forms of PsA more frequently than those without FH (86.4% vs. 70%; p< 0.001), as well as a younger age at disease onset (Table 1). The latency period between the onset of Pso and the development of arthritis was longer in patients with FH (median time: 9.6 vs. 4.3 years; log-rank: p< 0.001; Figure 1). In the multivariable analysis, FH Pso/PsA (HR 0.88 (95% CI 0.78–0.99)) and a younger age at Pso onset (HR 1.03 (95% CI 1.02–1.04)) were associated with a delay in the onset of arthritis relative to Pso (Omnibus test: p< 0.001).

Conclusion: Family history of Pso/PsA in patients with Pso is associated with a longer time until the onset of arthritis. Therefore, patients with FH not only require a higher index of suspicion for PsA but also need longer follow-up periods to detect it. Collaboration between Dermatology and Rheumatology will be essential for early diagnosis and optimal management.

Supporting image 1Table 1. Descriptive summary of the most relevant collected variables

Supporting image 2Figure 1. Longer latency to arthritis. Median time: 10 years vs. 4 years (p < 0.001)


Disclosures: M. Flores: None; J. de Luque: None; M. Parra: None; A. Escudero Contreras: None; M. López-Montilla: None; C. López Medina: None.

To cite this abstract in AMA style:

Flores M, de Luque J, Parra M, Escudero Contreras A, López-Montilla M, López Medina C. Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients? [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/transition-from-psoriasis-to-psoriatic-arthritis-does-family-history-influence-the-time-to-onset-of-arthritis-in-psoriasis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transition-from-psoriasis-to-psoriatic-arthritis-does-family-history-influence-the-time-to-onset-of-arthritis-in-psoriasis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology